1. All-stage targeted red blood cell membrane-coated docetaxel nanocrystals for glioma treatment.
- Author
-
Ding Y, Xu Q, Chai Z, Wu S, Xu W, Wang J, Zhou J, Luo Z, Liu Y, Xie C, Lu L, and Lu W
- Subjects
- Animals, Cell Line, Tumor, Male, Drug Delivery Systems, Avidin administration & dosage, Avidin chemistry, Humans, Biotin chemistry, Biotin administration & dosage, Rats, Sprague-Dawley, Blood-Brain Barrier metabolism, Mice, Inbred BALB C, Mice, Nude, Docetaxel administration & dosage, Docetaxel pharmacokinetics, Docetaxel chemistry, Glioma drug therapy, Nanoparticles chemistry, Antineoplastic Agents administration & dosage, Antineoplastic Agents pharmacokinetics, Antineoplastic Agents chemistry, Antineoplastic Agents therapeutic use, Erythrocyte Membrane drug effects, Erythrocyte Membrane chemistry, Brain Neoplasms drug therapy
- Abstract
Challenges for glioma treatment with nanomedicines include physio-anatomical barriers (the blood-brain barrier and blood-brain tumor barrier), low drug loading capacity, and limited circulation time. Here, a red blood cell membrane-coated docetaxel drug nanocrystal (pV-RBCm-NC(DTX)), modified with pHA-VAP (pV) for all-stage targeting of glioma, was designed. The NC(DTX) core exhibited a high drug loading capacity but low in vivo stability, and the RBCm coating significantly enhanced the stability and prolonged in vivo circulation. Moreover, the Y-shaped targeting ligand pV was modified by a mild avidin-biotin interaction, which endowed RBCm-NC(DTX) with superior barrier-crossing ability and therapeutic efficacy. The integration of nanocrystal technology, cell membrane coating, and the avidin-biotin insertion method into this active targeting biomimetic formulation represents a promising drug delivery strategy for glioma., Competing Interests: Declaration of competing interest The authors declare no competing financial interest., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF